Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

Objective For the treatment of gastroesophageal reflux disease, intragastric pH should be lower than 4.0 for no more than 4 hours a day (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2004-10, Vol.76 (4), p.290-301
Hauptverfasser:	Sugimoto, Mitsushige, Furuta, Takahisa, Shirai, Naohito, Kajimura, Masayoshi, Hishida, Akira, Sakurai, Masaharu, Ohashi, Kyoichi, Ishizaki, Takashi
Format:	Artikel
Sprache:	eng
Schlagworte:	2-Pyridinylmethylsulfinylbenzimidazoles Administration, Oral Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - pharmacokinetics Anti-Ulcer Agents - pharmacology Area Under Curve Aryl Hydrocarbon Hydroxylases - genetics Benzimidazoles - administration & dosage Benzimidazoles - blood Benzimidazoles - pharmacokinetics Benzimidazoles - pharmacology Biological and medical sciences Cytochrome P-450 CYP2C19 Digestive system Drug Administration Schedule Female Gastric Acid - secretion Genotype Humans Male Medical sciences Mixed Function Oxygenases - genetics Omeprazole - analogs & derivatives Pharmacology. Drug treatments Polymorphism, Genetic - physiology Proton-Translocating ATPases - antagonists & inhibitors Rabeprazole Stomach - drug effects Stomach - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective For the treatment of gastroesophageal reflux disease, intragastric pH should be lower than 4.0 for no more than 4 hours a day (
ISSN:	0009-9236 1532-6535
DOI:	10.1016/j.clpt.2004.06.008